Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.2004110957PMID 15938034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of hypertension in patients with type 2 diabetes mellitus

  2013cited by this paper
• Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria

  2004cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

  2003cited by this paper
• 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis

  2003cited by this paper
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

  2003cited by this paper
• Treatment of hypertension in adults with diabetes.

  2003cited by this paper
• An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

  2003cited by this paper
• Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

  2003cited by this paper
• European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension

  2003cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

  2002cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• The African American Study of Kidney Disease and Hypertension (AASK): New Findings

  2001cited by this paper
• Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

  2000cited by this paper
• Low-Dose Ramipril Reduces Microalbuminuria in Type 1 Diabetic Patients Without Hypertension

  2000cited by this paper
• Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial.

  2000cited by this paper
• SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

  2000cited by this paper
• Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

  1999cited by this paper
• Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria

  1999cited by this paper
• Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function

  1999cited by this paper
• Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

  1999cited by this paper
• Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Effects of Lisinopril and Nifedipine on the Progression to Overt Albuminuria in IDDM Patients With Incipient Nephropathy and Normal Blood Pressure

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy

  1997cited by this paper
• Effective Postponement of Diabetic Nephropathy With Enalapril in Normotensive Type 2 Diabetic Patients With Microalbuminuria

  1997cited by this paper
• Effects of Long‐term Enalapril Treatment on Persistent Microalbuminuria in Normotensive Type 2 Diabetic Patients: Results of a 4‐year, Prospective, Randomized Study

  1996cited by this paper
• Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy.

  1996cited by this paper
• Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria

  1996cited by this paper
• Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

  1996cited by this paper
• Prevention of diabetic renal disease with special reference to microalbuminuria.

  1995cited by this paper
• Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria.

  1994cited by this paper
• Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells.

  1994cited by this paper
• Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients

  1993cited by this paper

• Stachydrine Protects Against Diabetic Nephropathy Through Modulating Autophagy, Oxidative Stress, and Apoptosis via the AMPK/mTOR and Nrf2/HO-1 Pathways

  2025cites this paper
• Effects of allisartan‐isoproxil‐based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia

  2024cites this paper
• Diabetic Kidney Disease: An Update.

  2023cites this paper
• Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction

  2023cites this paper
• Yiqi Qingre Xiaozheng formula protects against diabetic nephropathy by restoring autophagy in mice

  2023cites this paper
• Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease

  2021cites this paper
• Efficacy of Tripterygium wilfordii Hook F on animal model of Diabetic Kidney Diseases: A systematic review and meta-analysis.

  2021cites this paper
• Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities

  2020cites this paper
• Enfermedad renal crónica en el paciente anciano

  2019cites this paper
• [Chronic kidney disease in the elderly patient].

  2017cites this paper
• Blood pressure-lowering agents response : a systematic review and genome wide study

  2017cites this paper
• Consenso de Hipertensión Arterial Sistémica en México

  2016cites this paper
• Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats

  2016cites this paper
• Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study

  2016cites this paper
• The cost–effectiveness of irbesartan for hypertension

  2015cites this paper
• The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review

  2013cites this paper
• PREVALENCE OF MICROALBUMINURIA AND ASSOCIATED FACTORS AMONG HYPERTENSIVE PATIENTS AT MUHIMBILI NATIONAL HOSPITAL DAR ES SALAAM

  2013cites this paper
• Nephropathy following type 2 diabetes mellitus in Tunisian population.

  2012cites this paper
• The Role of Irbesartan in the Treatment of Patients with Hypertension

  2012cites this paper
• Diabetic nephropathy among Mexican Americans

  2012cites this paper
• [Irbesartan in clinical practice].

  2012cites this paper
• Irbesartan

  2012cites this paper
• Evolution of Treatment for Diabetic Nephropathy: Historical Progression from RAAS Inhibition and Onward

  2011cites this paper
• Special considerations on the management of Latino patients with type 2 diabetes mellitus

  2011cites this paper
• Long‐term results of pancreas transplantation in patients older than 50 years

  2011cites this paper
• Long-term use and tolerability of irbesartan for control of hypertension

  2011cites this paper
• Guías clínicas para la detección, prevención, diagnóstico y tratamiento de hipertensión arterial sistémica en México (2008)

  2008cites this paper
• Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.

  2008cites this paper
• Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in prevention of nephropathy and cardiovascular disease in diabetics

  2008cites this paper
• Nutrition et insuffisance rénale chronique

  2007cites this paper
• Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone

  2007cites this paper
• Microalbuminuria screening in patients with hypertension: recommendations for clinical practice

  2007cites this paper
• Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population.

  2007cites this paper
• Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α

  2006cites this paper